Endometrial pathology in postmenopausal tamoxifen treatment: comparison between gynaecologically symptomatic and asymptomatic breast cancer patients
Open Access
- 1 April 1999
- journal article
- Published by BMJ in Journal of Clinical Pathology
- Vol. 52 (4), 278-282
- https://doi.org/10.1136/jcp.52.4.278
Abstract
AIMS: To evaluate whether endometrial pathology is more likely to be diagnosed in gynaecologically symptomatic rather than in gynaecologically asymptomatic postmenopausal breast cancer patients with tamoxifen treatment; and to evaluate the possible influence of various clinical factors on the incidence of endometrial pathology. METHODS: Endometrial histological findings, transvaginal ultrasonographic endometrial thickness, demographic characteristics, health habits, and risk factors for endometrial cancer were compared between 14 gynaecologically symptomatic (group I) and 224 gynaecologically asymptomatic (group II) postmenopausal breast cancer patients with tamoxifen treatment. RESULTS: Overall, 28.6% of the study population had endometrial pathology. The incidence of overall positive endometrial histological findings was significantly higher in group I than in group II (92.9% v 24.6%, p < 0.0001). Atrophic endometrium was more common in group II than in group I (75.3% v 7.1%, p < 0.0001). Most other endometrial pathology was significantly more common in group I than in group II (endometrial hyperplasia, 35.7% v 5.6%, p < 0.0001; endometrial polyps, 35.7% v 13.4%, p < 0.0111; endometrial carcinoma, 21.5% v 0.9%, p < 0.0001). Endometrial pathology appeared considerably later in the gynaecologically asymptomatic patients than in gynaecologically symptomatic patients (p = 0.0002). Vaginal bleeding or spotting occurred exclusively in group I. The incidence of endometrial pathology in the entire study population was consistent with that reported elsewhere, and higher than that reported for healthy postmenopausal women. CONCLUSIONS: Endometrial pathology is more likely to be diagnosed in gynaecologically symptomatic postmenopausal breast cancer patients with tamoxifen treatment, and after a shorter duration of time, than in gynaecologically asymptomatic patients.Keywords
This publication has 42 references indexed in Scilit:
- Value of Sonohysterography in Asymptomatic Postmenopausal Tamoxifen-Treated PatientsGynecologic Oncology, 1997
- Second Cancers After Adjuvant Tamoxifen Therapy for Breast CancerJNCI Journal of the National Cancer Institute, 1996
- Time-Dependent Effect of Tamoxifen Therapy on Endometrial Pathology in Asymptomatic Postmenopausal Breast Cancer PatientsInternational Journal of Gynecological Pathology, 1996
- Endometrial Cancer following Breast CancerEpidemiology, 1996
- A Retrospective Study of Tamoxifen and Endometrial Cancer in Breast Cancer PatientsGynecologic Oncology, 1995
- Continuous Tamoxifen Treatment in Asymptomatic, Postmenopausal Breast Cancer Patients Does Not Cause Aggravation of Endometrial PathologiesGynecologic Oncology, 1994
- Endometrial Changes with Tamoxifen: Comparison between Tamoxifen-Treated and Nontreated Asymptomatic, Postmenopausal Breast Cancer PatientsGynecologic Oncology, 1994
- Endometrial lesions in patients undergoing tamoxifen therapyInternational Journal of Gynecology & Obstetrics, 1991
- Oncogenic potential of tamoxifen on endometria of postmenopausal women with breast cancer—Preliminary reportGynecologic Oncology, 1991
- Incidence of New Primary Cancers After Adjuvant Tamoxifen Therapy and Radiotherapy for Early Breast CancerJNCI Journal of the National Cancer Institute, 1991